Elsewhere on Ulster
This project is funded by:
Oral cancer remains a significant clinical challenge, with outcomes strongly influenced by the stage at which disease is identified. Oral potentially malignant disorders (OPMDs) can precede the development of oral cancer, but determining which lesions are most likely to progress remains difficult. There is therefore a need for minimally invasive approaches that can provide additional molecular information to support risk assessment, monitoring and referral decisions.
This PhD will investigate precision oral liquid biopsy as a new approach to molecular risk stratification of OPMDs. Building on established expertise in oral biofluid sampling and hydrogel-based diagnostic technologies, the project will develop and evaluate minimally invasive methods for capturing disease-associated biomarkers from the oral environment.
The researcher will investigate complementary molecular biomarkers associated with inflammation, potentially malignant change and oral cancer, and assess their recovery using novel sampling approaches. A key focus will be determining whether combinations of biomarkers can distinguish malignant or potentially malignant changes from common inflammatory oral conditions. Statistical and machine-learning approaches will be explored to integrate molecular and clinical data and identify clinically meaningful biomarker signatures and risk-stratification models.
The project will provide interdisciplinary training across precision diagnostics, biomaterials, molecular biomarker analysis, experimental design and data science, with opportunities to contribute to the development of next-generation approaches for earlier and more personalised disease assessment.
Ultimately, the research aims to establish the scientific foundations for a minimally invasive diagnostic strategy capable of supporting improved identification and monitoring of patients at greatest risk of oral cancer.
Please note: Research Proposal - 5 pages in total
The proposal must include:
Please also note that the use of AI in generating the research proposal is prohibited.
Important Information: Applications for more than one PhD studentship are welcome, however if you apply for more than one PhD project within Biomedical Sciences/Pharmacy and Pharmaceutical Sciences, your first application on the system will be deemed your first-choice preference and further applications will be ordered based on the sequential time of submission.
If you are successfully shortlisted, you will be interviewed only on your first-choice application and ranked accordingly. Those ranked highest will be offered a PhD studentship.
In the situation where you are ranked highly and your first-choice project is already allocated to someone who was ranked higher than you, you may be offered your 2nd or 3rd choice project depending on the availability of this project.
Applicants should hold, or expect to obtain, a First or Upper Second Class Honours Degree in a subject relevant to the proposed area of study.
We may also consider applications from those who hold equivalent qualifications, for example, a Lower Second Class Honours Degree plus a Master’s Degree with Distinction.
In exceptional circumstances, the University may consider a portfolio of evidence from applicants who have appropriate professional experience which is equivalent to the learning outcomes of an Honours degree in lieu of academic qualifications.
If the University receives a large number of applicants for the project, the following desirable criteria may be applied to shortlist applicants for interview.
The University is an equal opportunities employer and welcomes applicants from all sections of the community, particularly from those with disabilities.
Appointment will be made on merit.
This project is funded by:
PhD Scholarships are available for this project and will cover:
To be eligible for these scholarships applicants must: be a UK or Irish national; or have pre-settled or settled status; or have indefinite leave to remain or enter.
Applicants should also meet the residency criteria which requires that they have lived in the EEA, Switzerland, the UK or Gibraltar for at least the three years preceding the start date of the research degree programme i.e. September 2027.
Applicants who already hold a doctoral degree or who have been registered on a programme of research leading to the award of a doctoral degree on a full-time basis for more than one year, or part-time equivalent, funded from any source, including self-financing students, are NOT eligible to apply for an award.
Students in full-time employment are not eligible for an award.
Due consideration should be given to financing your studies.
Part-time PhD scholarships may be available at a 0.5 pro rata rate of the full-time scholarship, which would require a six-year registration period.
The University will award a successful candidate one of the following scholarships for the project, depending on the funding available at the time an admissions offer is made:
Please note that the Terms and Conditions for scholarships are subject to change for 2027/28.
Iocca O, Sollecito TP, Alawi F, et al. Potentially malignant disorders of the oral cavity and oral dysplasia: a systematic review and meta-analysis of malignant transformation rate by subtype. Oral Oncology. 2020;102:104557.
Bastías D, et al. Salivary biomarkers for oral cancer detection: a scoping review. Diagnostics. 2024. This provides a useful overview of salivary molecular biomarkers investigated for oral squamous cell carcinoma and supports the rationale for minimally invasive biomarker-based diagnostics.
Adeoye J, et al. Artificial intelligence in salivary biomarker discovery and validation for oral and maxillofacial diseases: a systematic review. Journal of Oral Pathology & Medicine. 2024. This highlights the potential for machine-learning approaches to integrate salivary biomarker data for disease diagnosis and monitoring.
Niekra P, et al. The role of liquid biopsy in the diagnosis of oral squamous cell carcinoma: a systematic review. 2026. This recent review highlights the emerging role of miRNA, cell-free nucleic acids and tumour-associated DNA in oral liquid-biopsy approaches.
Şengün DN, et al. Emerging diagnostic strategies for oral cancer and oral potentially malignant disorders. Diagnostics. 2026;16(9):1364. This recent review provides a broad overview of non- and minimally invasive diagnostic technologies and their potential role within future oral cancer pathways.
Submission deadline
Friday 8 January 2027
04:00PM
Interview Date
between 8 -16 February 2027
Preferred student start date
13 September 2027
Telephone
Contact by phone
Email
Contact by email